QSAR studies of indoyl aryl sulfides and sulfones as reverse transcriptase inhibitors

The inhibitory HIV reverse transcriptase activity of 172 non-nucleoside indoyl aryl sulfones and sulfides is studied with a QSAR analysis, in order to identify the molecular characteristics influencing the interaction with the reverse transcriptase enzyme. This work increases the available QSAR studies of indoyl aryl sulfones and sulfides using the reported experimental EC50 values against HIV-1 wild type (IIIB) in human T-lymphocyte (CEM) cells. Different approaches are proposed, involving 0D, 1D and 2D molecular descriptors from PaDEL freeware, and also based on flexible descriptors from CORAL freeware. Three models are finally presented, which correlate the inhibitory HIV reverse transcriptase activity with good accuracy. It is demonstrated that the established models are predictive in the validation process. The novelty of the present work relies on the development of structure-inhibitory HIV activity relationships, through a computational technique that does not require the knowledge of the molecular conformation during the structural representation. The obtained results would contribute to guide the design of more effective compounds for HIV treatment.

[1]  E. Crespan,et al.  High Potency of Indolyl Aryl Sulfone Nonnucleoside Inhibitors towards Drug-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutants Is Due to Selective Targeting of Different Mechanistic Forms of the Enzyme , 2005, Antimicrobial Agents and Chemotherapy.

[2]  R. Silvestri,et al.  Synthesis of Pyrryl Aryl Sulfones Targeted at the HIV‐1 Reverse Transcriptase , 1995, Archiv der Pharmazie.

[3]  E. De Clercq,et al.  Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. , 2000, Molecular pharmacology.

[4]  A. Bergamini,et al.  Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. , 2007, Journal of medicinal chemistry.

[5]  P. Duchowicz,et al.  Quantitative structure-property relationship analysis for the retention index of fragrance-like compounds on a polar stationary phase. , 2015, Journal of chromatography. A.

[6]  Sergio R. Ribone,et al.  Synthesis, biological evaluation and molecular modeling of 4,6-diarylpyrimidines and diarylbenzenes as novel non-nucleosides HIV-1 reverse transcriptase inhibitors. , 2012, European journal of medicinal chemistry.

[7]  Pablo R. Duchowicz,et al.  QSPR analysis for the retention index of flavors and fragrances on a OV-101 column , 2015 .

[8]  W. Greenlee,et al.  5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. , 1993, Journal of medicinal chemistry.

[9]  A. Tropsha,et al.  Beware of q2! , 2002, Journal of molecular graphics & modelling.

[10]  A. Bergamini,et al.  Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. , 2006, Journal of medicinal chemistry.

[11]  E. Novellino,et al.  Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. , 2000, Journal of medicinal chemistry.

[12]  S. Schenone,et al.  (Hetero)aroyl esters of 2-(N-phthalimido)ethanol and analogues: parallel synthesis, anti-HIV-1 activity and cytotoxicity , 2010, Medicinal Chemistry Research.

[13]  E. Clercq.  Highlights in the discovery of antiviral drugs: a personal retrospective. , 2010 .

[14]  Peng Zhan,et al.  HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design , 2013, Medicinal research reviews.

[15]  R. Di Santo,et al.  2H-Pyrrolo[3,4-b] [1,5]benzothiazepine derivatives as potential inhibitors of HIV-1 reverse transcriptase. , 2005, Farmaco.

[16]  Silvio Massa,et al.  Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. , 2003, Journal of medicinal chemistry.

[17]  E. Novellino,et al.  Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. , 2011, Journal of medicinal chemistry.

[18]  M. Shah,et al.  HIV combination products , 2007, Nature Reviews Drug Discovery.

[19]  CHUN WEI YAP,et al.  PaDEL‐descriptor: An open source software to calculate molecular descriptors and fingerprints , 2011, J. Comput. Chem..

[20]  A. Bergamini,et al.  Indolyl Aryl Sulphones as HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Synthesis, Biological Evaluation and Binding Mode Studies of New Derivatives at Indole-2-carboxamide , 2006, Antiviral chemistry & chemotherapy.

[21]  W. Greenlee,et al.  5‐Chloro‐3‐(phenylsulfonyl)indole‐2‐carboxamide: A Novel, Non‐ Nucleoside Inhibitor of HIV‐1 Reverse Transcriptase. , 1994 .

[22]  Christopher M. Bailey,et al.  C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors. , 2008, Bioorganic & medicinal chemistry.

[23]  R. Musah.  The HIV-1 nucleocapsid zinc finger protein as a target of antiretroviral therapy. , 2004, Current topics in medicinal chemistry.

[24]  K. Kehn-Hall,et al.  Novel Neuroprotective GSK-3β Inhibitor Restricts Tat-Mediated HIV-1 Replication , 2013, Journal of Virology.

[25]  In-silico design and study of novel piperazinyl β-carbolines as inhibitor of HIV-1 reverse transcriptase , 2015, Medicinal Chemistry Research.

[26]  E. Castro,et al.  Conformation-Independent QSPR Approach for the Soil Sorption Coefficient of Heterogeneous Compounds , 2016, International journal of molecular sciences.

[27]  G. McGaughey,et al.  Novel indole-3-sulfonamides as potent HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). , 2008, Bioorganic & medicinal chemistry letters.

[28]  S. Chander,et al.  Design, synthesis of new β-carboline derivatives and their selective anti-HIV-2 activity. , 2015, Bioorganic & medicinal chemistry letters.

[29]  Kunal Roy,et al.  Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment , 2015 .

[30]  E. Castro,et al.  QSAR analysis on Spodoptera litura antifeedant activities for flavone derivatives. , 2009, The Science of the total environment.

[31]  A. Fauci,et al.  Progress in drug therapies for HIV infection. , 1988, Public health reports.

[32]  G. Maga,et al.  Mechanism of Interaction of Novel Indolylarylsulfone Derivatives with K103N and Y181I Mutant HIV-1 Reverse Transcriptase in Complex with its Substrates , 2011, Antiviral chemistry & chemotherapy.

[33]  S. Miertus,et al.  Synthesis and biological evaluation of new simple indolic non peptidic HIV Protease inhibitors: the effect of different substitution patterns. , 2014, Bioorganic & medicinal chemistry.

[34]  I G Williams,et al.  ENFUVIRTIDE (FUZEON®): THE FIRST FUSION INHIBITOR , 2003, International journal of clinical practice.

[35]  O. Weislow,et al.  Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase , 1993, Antimicrobial Agents and Chemotherapy.

[36]  A. Defant,et al.  Design, Synthesis, and Biological Evaluation of Novel 2H‐Pyran‐2‐one Derivatives as Potential HIV‐1 Reverse Transcriptase Inhibitors , 2015, Archiv der Pharmazie.

[37]  Xin He,et al.  Development of benzimidazole derivatives to inhibit HIV-1 replication through protecting APOBEC3G protein. , 2015, European journal of medicinal chemistry.

[38]  S. Zanoli,et al.  Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex. , 2009, Antiviral research.

[39]  Yusnarida Eka Nizmi,et al.  PERAN UNAIDS (THE JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS) DALAM PENANGANAN HIV/AIDS DI ZIMBABWE , 2015 .

[40]  C. Pannecouque,et al.  Inhibition of HIV-1 Replication by a Bis-Thiadiazolbenzene-1,2-Diamine That Chelates Zinc Ions from Retroviral Nucleocapsid Zinc Fingers , 2010, Antimicrobial Agents and Chemotherapy.

[41]  Williams Ig,et al.  Enfuvirtide (Fuzeon): the first fusion inhibitor. , 2003 .

[42]  Shane Weaver,et al.  The importance of the domain of applicability in QSAR modeling. , 2008, Journal of molecular graphics & modelling.

[43]  R. Silvestri,et al.  Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. , 2004, Journal of medicinal chemistry.

[44]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[45]  Kunal Roy,et al.  QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-state parameters. , 2004, Bioorganic & medicinal chemistry.

[46]  A. Coluccia,et al.  Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. , 2005, Journal of medicinal chemistry.

[47]  E. De Clercq,et al.  First synthesis and evaluation of the inhibitory effects of aza analogues of TSAO on HIV-1 replication. , 2005, Journal of medicinal chemistry.

[48]  Roberto Todeschini,et al.  Comments on the Definition of the Q2 Parameter for QSAR Validation , 2009, J. Chem. Inf. Model..

[49]  E. Novellino,et al.  Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. , 2009, Journal of medicinal chemistry.

[50]  M. Wainberg,et al.  Biochemical Mechanism of HIV-1 Resistance to Rilpivirine* , 2012, The Journal of Biological Chemistry.